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GM-CSF Induces Expression of Soluble VEGF
Receptor-1 from Human Monocytes
and Inhibits Angiogenesis in Mice
VEGF-A signals through VEGF receptor 1 (VEGFR-1)
(Flt-1) and VEGFR-2 (KDR) (Matsumoto and Claesson-
Welsh, 2001). Structurally, both VEGF receptors have
seven immunoglobulin (Ig)-like domains in their extracel-
lular regions and two tyrosine kinase domains, and VEGF
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binds at the second and third Ig-like domain in both2 The Ohio State Biochemistry Program
VEGFR-1 and VEGFR-2 (Wiesmann et al., 1997). In an3 The Integrated Biomedical Science Graduate Program
adult, monocytes express solely VEGFR-1 (Barleon etCollege of Medicine and Public Health
al., 1996), which is responsible for relaying VEGF signals4 Department of Pathology
(Neufeld et al., 1999). Endothelial cells express both5 Department of Internal Medicine
VEGFR-1 and VEGFR-2 (Neufeld et al., 1999), and while6 Department of Obstetrics and Gynecology
VEGFR-2 activates cellular signaling, VEGFR-1 acts asDivision of Gynecologic Oncology
a “sink” on these cells to sequester VEGF from VEGFR-2.The Ohio State University
Mice expressing the extracellular domain of VEGFR-1Columbus, Ohio 43210
lacking a functional tyrosine kinase domain develop nor-
mal blood vessels and survive. In contrast, null muta-
tions of the VEGFR-1 gene results in death early in em-Summary
bryogenesis due to a disorganization of blood vessels.
These data suggest an important regulatory role in vivoGM-CSF promotes homeostasis of myeloid cells. We
for VEGFR-1 (Risau, 1997; Ferrara et al., 1996). Otherreport that GM-CSF upregulates mRNA and protein
mechanisms used by endothelial cells to regulate VEGFproduction of the soluble form of membrane bound
include the production of an alternatively spliced mRNAVEGF receptor-1 (sVEGFR-1) in human monocytes.
variant of VEGFR-1, soluble VEGFR-1 (sVEGFR-1) (Ken-This sVEGFR-1 was biologically active, as cell-free su-
dall et al., 1996). Soluble VEGFR-1 is identical to mem-pernatants fromGM-CSF-stimulatedmonocytes blocked
brane bound VEGFR-1, except it lacks the transmem-detection of endogenously expressed VEGF and inhib-
brane region necessary to attach the receptor to theited endothelial cell migration and tube formation,
cell membrane (Kendall et al., 1996) and any kinaseeven in the presence of exogenous rhVEGF. VEGF ac-
activity. Since receptor dimerization is essential for sig-tivity was recovered by neutralizing sVEGFR-1. To de-
naling through VEGF receptors, sVEGFR-1 sequesterstermine whether these events were important in vivo,
VEGF from activating either VEGFR-1 (on monocytes)Matrigel plugs were incubated with rhVEGF, rhGM-CSF,
or VEGFR-2 (on endothelial cells) by inhibiting dimeriza-or rhGM-CSF/rhVEGF and injected into mice. Plugs
tion of VEGFRs (Roeckl et al., 1998). Once VEGFRscontaining GM-CSF or GM-CSF/VEGF had less endo-
become activated, signaling follows classical receptorthelial cell invasion than plugs containing rhVEGF and
tyrosine kinase activating pathways (Kliche and Wal-were similar to plugs incubated with PBS alone. Neu-
tenberger, 2001).tralizing antibodies specific for sVEGFR-1 injected in
A relationship between VEGF and GM-CSF has yet tothese plugs reversed the effects of GM-CSF or GM-
be elucidated. Under immune stress, growth factors likeCSF/VEGF, while an isogenic antibody did not. Thus,
M-CSF and GM-CSF stimulate differentiation of hemato-GM-CSF and monocytes play a vital role in angiogen-
poietic progenitor stem cells in the bone marrow to theesis through the regulation of VEGF and sVEGFR-1.
myeloid compartment and influence their movement
into the bloodstream (Wognum et al., 1994). In response
Introduction
to an infectious challenge, monocyte and macrophage
recruitment and accumulation at involved sites is advan-
GM-CSF drives hematopoietic precursor cells to mature tageous for host defense; however, in alternative set-
granulocytes, macrophages, or dendritic cells (Wognum tings like breast cancer, growth factors like M-CSF in-
et al., 1994) and is used clinically to accelerate bone duce the release of VEGF by these monocytes (Eubank
marrow recovery and increase the production of white et al., 2003) and stimulate tumor metastases (Lin et al.,
blood cells to facilitate host defense (Bleharski et al., 2001). Data presented in our current study suggest that
2003). GM-CSF reduces VEGF activity by inducing secretion
We reported that M-CSF induces human monocytes of the soluble form of VEGFR-1 by human monocytes
to produce and release biologically active VEGF (Eubank and thus by reducing biologically active VEGF available
et al., 2003). VEGF (isoform-A) is an angiogenic factor for angiogenesis.
that promotes blood vessel formation in human cancer This study demonstrates that recombinant GM-CSF
(Leung et al., 1989) and plays a dominant role in human stimulates human monocytes to transcribe and translate
health and disease as a regulator of new blood vessel the alternatively spliced and soluble form of VEGF recep-
growth and an inducer of vascular permeability (Dvorak, tor-1. By utilizing both in vitro angiogenesis assays (en-
2000). VEGF-A is also highly expressed during episodes dothelial cell tube formation and migration) and in vivo
of hypoxia (Cao et al., 1998). Matrigel plug assays in mice, we demonstrate that
sVEGFR-1 sequesters VEGF from endothelial cells and
interrupts angiogenesis. Our model for the inhibition of*Correspondence: marsh.2@osu.edu
Immunity
832
Figure 1. Proposed Model for the Inhibition of Pathological Angiogenesis
This figure was based on models published by Scalerandi et al. (2002), Heuser et al. (1984), Shweiki et al. (1995), and Clarijs et al. (2003).
angiogenesis via sequestration of VEGF by sVEGFR-1 rhGM-CSF (100 ng/ml) or rhM-CSF (100 ng/ml) (positive
control) for 36 hr, followed by the addition of both 35S-(Figure 1) involves stimulation of local monocytes/mac-
rophages by direct GM-CSF administration at the site methionine and 35S-cysteine. Our results indicate that
there is no significant difference in VEGF protein produc-of the primary tumor.
tion between untreated and GM-CSF-stimulated mono-
cytes (Figure 2C). Furthermore, real-time PCR analysisResults
showed no difference in VEGF mRNA transcription (data
not shown) or cell toxicity due to GM-CSF stimulationGM-CSF Reduces VEGF Detection
after 24 hr (data not shown) to explain the observed dif-in the Supernatants of Stimulated Monocytes
ferences.Previously, we reported that M-CSF induces human
monocytes to upregulate both VEGF mRNA transcrip-
tion and protein production (Eubank et al., 2003). Since Recombinant VEGF Added to the Supernatants
of GM-CSF-Stimulated Monocytes CannotGM-CSF is also a survival factor for monocytes, we
compared the levels of VEGF in the supernatants from Be Detected by ELISA
We next speculated that GM-CSF-stimulated mono-nonstimulated and rhGM-CSF (100 ng/ml)-stimulated
monocytes and expressed these values per viable cytes released an inhibitory factor into the supernatant
that blocked antigenic detection of VEGF by ELISA. Wemonocyte. The data showed that GM-CSF-stimulated
monocytes had significantly less VEGF than nonstimu- added recombinant human (rh)VEGF into supernatants
generated by untreated, rhM-CSF-, and rhGM-CSF-lated samples, as detected by VEGF ELISA at both 24
and 48 hr (Figure 2A). stimulated monocytes and incubated these samples at
37C for 30 min. While the supernatants of monocytes
stimulated with GM-CSF blocked detection of rhVEGF,The Reduction in VEGF Detection from GM-CSF-
supernatants from non- or M-CSF-stimulated samplesStimulated Monocytes Not Due to Sequestration
did not (Figure 3A). These data suggest that GM-CSFof VEGF within the Cells
stimulated the release of a neutralizing factor in theseBecause there was reduced VEGF in the supernatants
supernatants that sequestered rhVEGF from antigenicof GM-CSF-stimulated monocytes compared to non-
detection by ELISA. We hypothesized that the VEGFstimulated cells, we considered that this loss in VEGF
inhibitory factor present in the supernatants was thedetection might be from VEGF sequestration intracellu-
alternatively spliced sVEGFR-1. Thus, we assayed thelarly in GM-CSF-treated cells. Monocytes were left un-
ability of recombinant sVEGFR-1 to mask rhVEGF fromtreated or treated with rhGM-CSF (100 ng/ml) for 2 and
detection by VEGF ELISA. 1, 8, and 16 ng/ml sVEGFR-124 hr and were assayed for VEGF in monocyte whole-
was incubated with 600 pg/ml rhVEGF at 37C for 30 mincell lysates. The data indicate that at 24 hr, there was
and subjected to VEGF ELISA. There was a significant,significantly less VEGF sequestered within monocytes
dose-dependent reduction in the detection of rhVEGFtreated with GM-CSF than in nontreated samples (Fig-
due to the presence of recombinant sVEGFR-1 (Fig-ure 2B).
ure 3B).Because VEGF levels were insufficient in the superna-
tants of nonstimulated or GM-CSF-stimulated cells for
immunoprecipitation studies, and because the primary Both sVEGFR-1 mRNA and Protein Levels
Are Significantly Increased in Responsestructure of VEGF contains 11% methionines and cyste-
ines, we chose to metabolically label VEGF by using 35S- to GM-CSF Treatment
Since rhVEGFR-1 induced a dose-dependent reductionmethionine and 35S-cysteine to determine differences in
VEGF protein production. Freshly isolated monocytes in rhVEGF detection, we assayed each supernatant of
untreated, M-CSF-, and GM-CSF-stimulated monocyteswere either left nonstimulated or were stimulated with
GM-CSF Inhibits Angiogenesis in Mice
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Figure 2. The Reduction in VEGF Detection
from GM-CSF-Stimulated Monocytes Was
Not Due to Sequestration of VEGF within
the Cells
(A) Monocytes were left nonstimulated (white)
or were stimulated with GM-CSF (100 ng/ml)
(black) for 24 and 48 hr, and cell-free superna-
tants were subjected to VEGF ELISA. There
was less VEGF detected by ELISA per mono-
cyte in the GM-CSF-stimulated samples
compared to nonstimulated samples (*p 
0.01 and **p  0.001). These data represent
the mean  SEM calculated from three inde-
pendent experiments.
(B) Monocytes were left untreated (white) or
were stimulated with GM-CSF (100 ng/ml)
(black) for 2 and 24 hr. Cell lysates were as-
sayed for VEGF by ELISA. At 24 hr, there is
significantly less VEGF sequestered within
monocytes due to GM-CSF treatment relative
to untreated samples (*p  0.05). These data
represent the mean  SEM calculated from
four independent experiments.
(C) Monocytes were left nonstimulated (NS)
or were stimulated with M-CSF (100 ng/ml) (M-CSF) or GM-CSF (100 ng/ml) (GM-CSF) and were labeled with 35S-Methionine/Cysteine. VEGF
was purified from the cell-free supernatants by using heparin-agarose beads and separated on a SDS-PAGE gel, and densitometry was
performed by using a phosphorimager. The VEGF band on the PAGE gel was clarified by detection of the band at the predicted size and was
compared to the band at the same size purified from the supernatants of M-CSF-stimulated monocytes, used as a positive control. The
photograph is representative of three independent experiments.
for endogenously expressed sVEGFR-1. An ELISA se- led us to hypothesize that GM-CSF induced monocytes
to release sVEGFR-1 into their supernatants.lective for human sVEGFR-1 showed that rhGM-CSF
(100 ng/ml)-treated monocytes produce a significant
amount of sVEGFR-1 compared to both non- and M-CSF- Soluble VEGFR-1 Production Correlates to Loss
in VEGF Detectionstimulated cells (Figure 4A).
To determine if GM-CSF induced transcription of To evaluate the possibility that preformed VEGF:sVEGFR-1
complexes existed within the cell, we either left mono-sVEGFR-1 in human monocytes, primers and a probe
specific for sVEGFR-1 mRNA were designed, and real- cytes untreated or treated them with rhGM-CSF (100
ng/ml) for 24 hr and assayed both supernatant and celltime PCR analysis was performed. After stimulation of
monocytes with rhGM-CSF, the sVEGFR-1 mRNA peak lysate for the presence of sVEGFR-1. Significant con-
centrations of sVEGFR-1 were released into the super-was detected at 24–48 hr, and this peak was followed
by a decline in production at 72 hr (Figure 4B). These natant compared to that remaining within the cell; thus,
the availability of sVEGFR-1 for preexisting complex for-data indicate a significant increase in the transcription
of sVEGFR-1 mRNA in response to GM-CSF. These data mation was limited (Figure 4C).
Figure 3. Recombinant sVEGFR-1 Masks
VEGF from ELISA Detection
(A) Monocytes were left untreated (NS) or
were treated with GM-CSF (100 ng/ml) (GM)
for 24 hr. Supernatants were collected and
subjected to VEGF ELISA. 450 pg/ml recom-
binant VEGF (rhVEGF added) was incubated
with these supernatants at 37C for 30 min,
and supernatants were subjected to VEGF
ELISA (NS sups  rhVEGF) and (GM sups 
rhVEGF). There are significant differences in
rhVEGF concentrations in both GM-CSF-
stimulated samples compared to nonstimu-
lated samples (*p  0.001), but there is no
difference between the GM-CSF-stimulated
samples (GM sups) alone versus GM-CSF-
stimulated supernatants supplemented with
rhVEGF (GM sups  rhVEGF) (p  0.85).
These data represent the mean SEM calcu-
lated from three independent experiments.
(B) Increasing concentrations of recombinant sVEGFR-1 (1, 8, and 16 ng/ml) were incubated with 600 pg/ml rhVEGF, and VEGF ELISA was
performed to investigate the ability of sVEGFR-1 to mask VEGF from antigenic detection of the ELISA. There is a significant dose-dependent
decrease in the detection of rhVEGF due to the presence of sVEGFR-1 (*p 0.01 versus VEGF sVEGFR-1 [1 ng/ml]; **p  0.001 versus VEGF
added; ***p 0.001 versus VEGF sVEGFR-1 [1 ng/ml]). These data represent the mean SEM calculated from three independent experiments.
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Figure 4. GM-CSF Augments sVEGFR-1 mRNA Transcription and Protein Production While Concomitantly Reducing the Detection of VEGF
by ELISA
(A) Monocytes were left nonstimulated or were stimulated with M-CSF (100 ng/ml) or GM-CSF (100 ng/ml) for 24 hr, and the supernatants
were subjected to sVEGFR-1 ELISA. GM-CSF-stimulated supernatants have significantly increased levels of sVEGFR-1 compared to M-CSF-
stimulated or nonstimulated controls (*p 0.001). These data represent the mean SEM calculated from seven independent monocyte donors.
(B) Monocytes were left nonstimulated (white) or were stimulated with GM-CSF (100 ng/ml) (black) for 4, 16, 24, 48, or 72 hr, and total cellular
RNA was subjected to real-time PCR. sVEGFR-1 mRNA levels were significantly higher at both 24 and 48 hr versus nonstimulated samples
at the same time points (*p  0.01 and **p  0.001). These data represent the mean  SEM calculated from three independent experiments.
(C) Monocytes were left nonstimulated or were stimulated with GM-CSF (100 ng/ml) for 24 hr. Supernatants (black) and cell lysates (white)
were subjected to sVEGFR-1 ELISA. There is significantly more sVEGFR-1 released into the supernatant than what remains within the cells
(*p  0.001). These data represent the mean  SEM calculated from six individual monocyte donors.
(D) Monocytes were left nonstimulated or were stimulated with 0.1, 1, 10, or 100 ng/ml GM-CSF for 48 hr, and supernatants were subjected
to sVEGFR-1 ELISA. There is a significant increase in sVEGFR-1 in both the 10 ng/ml and 100 ng/ml GM-CSF-treated samples compared to
the 0, 0.1, and 1 ng/ml GM-CSF-stimulated samples (*p  0.01 versus 0, 0.1, and 1 ng/ml GM-CSF-treated samples; **p  0.05 versus 0, 0.1,
1, and 10 ng/ml GM-CSF-treated samples). These data represent the mean  the SEM from three independent monocyte donors.
(E) Supernatants from the GM-CSF dose-dependent trials in (D) were concomitantly assayed by VEGF ELISA to analyze the concentration of
GM-CSF that reduced VEGF antigenic detection by VEGF ELISA. GM-CSF at both 10 ng/ml and 100 ng/ml stimulates significant reduction of
VEGF in a dose-dependent manner compared to 0, 0.1, and 1 ng/ml GM-CSF-stimulated samples (*p  0.01 versus 0, 0.1, and 1 ng/ml
GM-CSF-treated samples). These data represent the mean  SEM from three independent monocyte donors.
(F) Monocytes were stimulated with GM-CSF (100 ng/ml) and were incubated for 24 hr. Supernatants were incubated with an antibody specific
for sVEGFR-1 (sVR1 Ab) (2.5 g/ml) or an isogenic IgG control antibody (IgG Ab) (2.5 g/ml) for 30 min at 37C and were then removed by
using protein G beads. Supernatants were subjected to VEGF ELISA ([GM sups  sVR1 Ab] and [GM sups  IgG Ab]) for the presence of
VEGF. rhVEGF (900 pg/ml) (rhVEGF Added) was incubated with some samples ([rhVEGF Added], [GM sups  sVR1 Ab  rhVEGF], and [GM
sups  IgG Ab  rhVEGF]) for 30 min and subjected to VEGF ELISA. Supernatants from GM-CSF-stimulated monocytes incubated with the
antibody for sVEGFR-1 allowed rhVEGF detection by ELISA, while the supernatants from GM-CSF-stimulated monocytes incubated with the
isogenic IgG antibody did not (*p  0.001 for VEGF detection versus GM sups  IgG Ab sample and no significant difference compared to
rhVEGF Added sample). These data represent the mean  SEM calculated from three individual monocyte donors.
GM-CSF Inhibits Angiogenesis in Mice
835
Figure 5. Supernatants from rhGM-CSF-Stimulated Monocytes Inhibit Angiogenesis Effects In Vitro
(A) HUVECs were cultured in Matrigel as follows: HUVECs with EBM media (1 ml) (HUVECs); cells  rhVEGF (2.5 ng/ml) (VEGF); cells  1 ml
supernatants from rhGM-CSF (100 ng/ml)-stimulated monocytes  VEGF (2.5 ng/ml) (GM-CSF sups  VEGF); cells  1 ml supernatants from
rhGM-CSF (100 ng/ml)-stimulated monocytes  VEGF (2.5 ng/ml)  -sVEGFR-1 neutralizing antibodies (2 g/ml) (GM-CSF sups  VEGF 
anti-VEGFR-1 Ab); or cells 1 ml supernatants from rhGM-CSF (100 ng/ml)-stimulated monocytes VEGF (2.5 ng/ml) IgG1 isotype antibodies
(2 g/ml) (GM-CSF sups  VEGF  IgG1 isotype Ab). Pictures are representative of three independent trials.
(B) Tubule branch points from HUVECs stimulated as indicated above were counted, and the sum of three different fields for each condition
was averaged. Supernatants from monocytes stimulated with GM-CSF supernatants  rhVEGF (2.5 ng/ml) (GM-CSF sups  VEGF) for 24 hr
significantly inhibited endothelial cells from forming tube branch points compared to the rhVEGF (2.5 ng/ml) control (VEGF), and inhibition
was not statistically different from cells in EBM alone (HUVECs). GM-CSF supernatants incubated with rhVEGF (2.5 ng/ml) and neutralizing
antibodies specific for sVEGFR-1 (2 g/ml) (GM-CSF sups  VEGF  -sVEGFR-1 Ab) rescued HUVEC tube formation and restored it to
levels similar to rhVEGF control levels; these levels were significantly different from levels of GM-CSF supernatants incubated with rhVEGF
(2.5 ng/ml) and IgG1 isotype antibodies (2 g/ml) (GM-CSF sups  VEGF  IgG1 isotype Ab) (*p  0.05 versus HUVECs, GM-CSF sups 
VEGF, and GM-CSF sups  VEGF  IgG1 isotype Ab). Error bars represent the mean  SEM calculated from three independent studies.
(C) HUVECs were grown on Matrigel as follows: HUVECs with EBM media (1 ml) (HUVECs); cells  rhVEGF (5 ng/ml) (VEGF); or cells  rhVEGF
(5 ng/ml)  rh sVEGFR-1 (50 ng/ml) (VEGF recomb. sVEGFR-1). The circular photographs are shown at 40 magnification. Black boxes
within the panels indicate areas at 200 magnification, which are shown below each panel. Arrows denote tubule formation. Photos are
representative of two independent trials.
(D) Quantification of tubule branch points from the photographs in (C). There are significantly more tubule branch points in the VEGF condition
versus media alone and VEGF  recombinant sVEGFR-1 (p  0.05 and p  0.01, respectively).
To determine the concentration of GM-CSF needed to dose-dependent decrease in VEGF detection (Fig-
ure 4E).induce monocyte production of sVEGFR-1, monocytes
were left nonstimulated or stimulated with 0.1, 1, 10, or
100 ng/ml rhGM-CSF for 48 hr, and the supernatants Antigenic Detection of rhVEGF by ELISA Is Rescued
with Neutralizing Antibodies Specific for sVEGFR-1were evaluated for sVEGFR-1 and VEGF by respective
ELISAs. GM-CSF induced a dose-dependent increase To ensure that sVEGFR-1 was responsible for masking
antigenic detection of VEGF, sVEGFR-1 was immunode-in sVEGFR-1 production (Figure 4D) and a concomitant
Immunity
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Figure 6. rhGM-CSF Treatment Inhibits Angiogenesis in a Matrigel Plug Assay in Mice
Qualitative representation of angiogenesis in mice in response to Matrigel plugs treated with the following conditions:
(A) Matrigel supplemented with PBS.
(B) Matrigel supplemented with rhVEGF (10 ng/ml).
(C) Matrigel supplemented with rhGM-CSF (10 ng/ml).
(D) Matrigel supplemented with rhGM-CSF (10 ng/ml)  rhVEGF (10 ng/ml).
(E) Matrigel supplemented with rhGM-CSF (100 ng/ml).
(F) Matrigel supplemented with rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml).
(G) Matrigel supplemented with rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)  -sVEGFR-1 antibodies (2 g/ml).
(H) Matrigel supplemented with rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)  IgG1 isotype antibodies (2 g/ml).
(I) Relative count of CD31 () cells (black) and CD68 () cells (mononuclear cells) (white) that penetrate the Matrigel plugs in response to
stimuli; cells were observed by using a 40 objective. There was significantly more CD31 () cells in Matrigel plugs treated with (B) rhVEGF
(10 ng/ml) alone and (G) GM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)  -sVEGFR-1 antibodies (2 g/ml) than in plugs treated with (E) GM-CSF
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pleted from the supernatants of 24 hr, rhGM-CSF (100 nant sVEGFR-1 (50 ng/ml) (Figure 5C). We speculate
that any tube formation of HUVECs in the basal mediang/ml)-stimulated monocytes by using specific neu-
tralizing antibodies targeting the extracellular domain of alone arises from VEGF produced by the endothelial
cells themselves (Uchida et al., 1994). Indeed, recombi-the sVEGFR-1. Next, rhVEGF (900 pg/ml) was added to
these sVEGFR-1-depleted supernatants, and superna- nant sVEGFR-1 significantly inhibited endothelial cell
tube formation compared to media alone and VEGF con-tants were assayed for VEGF by ELISA. Depletion of
sVEGFR-1 from these supernatants recovered the trol samples (Figure 5D). In addition, to corroborate the
HUVEC tube formation assay, we assayed the ability ofdetection of added rhVEGF. There was no statistical
difference between rhVEGF (900 pg/ml) alone and GM-CSF-stimulated supernatants from monocytes to
reduce HUVEC migration through a porous filter disksVEGFR-1-depleted supernatants  rhVEGF (900 pg/
ml). In contrast, the detection of rhVEGF was blocked by using rhVEGF as the chemoattractant. These results
were similar to those from the tube formation assayin supernatants immunodepleted by using an isotype
IgG1 antibody (Figure 4F). and demonstrated reduced endothelial cell migration in
response to conditioned supernatants from GM-CSF-
stimulated cells (data not shown).
Angiogenic Activity of VEGF on Endothelial Cells
Is Inhibited by the Presence of sVEGFR-1
Secreted by Monocytes GM-CSF Treatment Inhibits Angiogenesis
in a Matrigel Plug Assay in MiceEndothelial cell tube formation and migration are two
in vitro methods to measure the angiogenic effects on Our next objective was to determine if these in vitro
observations correlated to in vivo effects of GM-CSF oncells with growth factors like VEGF (Yahata et al., 2003).
To analyze the antiangiogenic activity of sVEGFR-1 pro- angiogenesis; thus, we used the Matrigel plug assay in
mice. Prior to injection, unpolymerized growth factor-duced by GM-CSF-stimulated monocytes, we cultured
human umbilical vein endothelial cells (HUVECs) in cell- reduced Matrigel matrix was supplemented with PBS
alone, with rhVEGF (10 ng/ml), or with rhVEGF (10free supernatants of non- or rhGM-CSF (100 ng/ml)-
stimulated monocytes (24 hr incubation) and incubated ng/ml)  recombinant human sVEGFR-1 (160 ng/ml) to
assess if recombinant sVEGFR-1 could inhibit angiogen-these HUVECs on growth factor-reduced Matrigel matrix
for 20 hr. Through qualitative observation (Figure 5A) esis and von Willebrand factor (vWf) () cell recruitment
within the Matrigel plugs augmented by VEGF as theand quantitative analysis of tube formation (Figure 5B),
the data indicate that GM-CSF-stimulated, monocyte- positive control. After 10 days, the mice were sacrificed,
and the plugs were removed, sectioned, and analyzedexpressed sVEGFR-1 inhibited tube formation in HU-
VECs in combination with added rhVEGF (2.5 ng/ml) for vWf () cells to identify endothelial cell recruitment.
VEGF-treated plugs significantly increased migration ofcompared to that induced by rhVEGF (2.5 ng/ml) alone
(positive control). To assure that sVEGFR-1 was respon- vWf () cells and blood vessel formation within the Ma-
trigel plugs compared to PBS-treated plugs (mean val-sible for the reduction in HUVEC capillary-like formation,
these supernatants were incubated with neutralizing an- ues: 28  1 vWf [] cells per HPF for VEGF; 15  1 vWf
() cells per HPF for PBS plugs) (p  0.001 for VEGF-tibodies specific for sVEGFR-1 or equal amounts of iso-
genic IgG antibodies. As expected, antibodies to sVEGFR-1 treated plugs versus PBS plugs). Additionally, those
plugs incubated with VEGF (10 ng/ml)  recombinantrestored tube formation to that induced by rhVEGF (2.5
ng/ml) alone. In contrast, HUVEC samples incubated with sVEGFR-1 (160 ng/ml) had significantly less vWf () cells
(mean value: 20  1 vWf [] cells per HPF) than theGM-CSF-stimulated supernatants or GM-CSF-stimulated
supernatants  rhVEGF (2.5 ng/ml)  isogenic IgG anti- VEGF (10 ng/ml)-treated plugs (p  0.001). These data
suggest that recombinant human sVEGFR-1 inhibitedbodies had substantially less tube formation than sam-
ples treated with antibodies to sVEGFR-1 (Figures 5A VEGF activity within these plugs.
We next incubated Matrigel with rhVEGF (10 ng/ml),and 5B). To verify that sVEGFR-1 can prevent tube for-
mation of endothelial cells, we cultured HUVECs alone, rhGM-CSF (10 ng/ml), rhGM-CSF (10 ng/ml)  rhVEGF
(10 ng/ml), rhGM-CSF (100 ng/ml), rhGM-CSF (100with rhVEGF (5 ng/ml), or with VEGF (5 ng/ml) recombi-
(100 ng/ml), (F) GM-CSF (100 ng/ml)  rhVEGF (10 ng/ml), or (H) GM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)  IgG isotype antibody (2 g/ml)
(*p  0.05).
(J) Total cell counts identified by H&E staining for cell nuclei that penetrated the Matrigel plugs in response to stimuli; cells were observed
by using a 40 objective. (E) GM-CSF (100 ng/ml)-treated plugs displayed reduced blood vessel presence within the plugs compared to (B)
rhVEGF (10 ng/ml) alone and those plugs containing (G) rhGM-CSF  VEGF  -sVEGFR-1 neutralizing antibodies. The (E) GM-CSF (100 ng/
ml)- and (C) GM-CSF (10 ng/ml)-treated plugs had less cells than plugs treated with (B) VEGF (10 ng/ml) or with (G) sVEGF-R Ab (*p  0.003
versus the GM-CSF (10 ng/ml)  VEGF (10 ng/ml) sample, **p  0.003 versus the GM-CSF [10 ng/ml] sample, and ***p  0.001 versus each
of the PBS, GM-CSF [100 ng/ml], and GM-CSF [100 ng/ml]  VEGF [10 ng/ml] samples). Values represent the number of total cell nuclei per
40 field. At least three mice were tested per group. Note: Large pictures are shown at 400 magnification, and insets are shown at 100
magnification for all samples.
(K) C57BL/6 mice were sacrificed, and bone marrow from the femur was collected. After washing in RPMI-1640, the bone marrow was cultured
and either left nonstimulated, stimulated with hGM-CSF (100 ng/ml), or stimulated with mGM-CSF (100 ng/ml). Every 2 days, the media was
collected and fresh media and GM-CSF treatment was administered. After 10 days, the plates were washed with PBS and pictures taken (5
per well).
(L) Cell counts represent the percentage of mGM-CSF activity (ability to induce murine bone marrow cell maturation) from Figure 7K. Human
GM-CSF induces murine bone marrow cell maturation significantly more than PBS treatment (nonstimulated) (p  0.05).
Immunity
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Figure 7. Investigation of the Mechanism of VEGFR-1 Expression and sVEGFR-1 Secretion from Human Monocytes
(A) A population of CD14 () cells isolated by flow cytometry by using -human CD14-phycoerythrin antibodies.
(B) Fresh CD14 () cells were analyzed for VEGFR-1 expression by using mouse -human VEGFR-1-phycoerythrin (shaded) and mouse
-human IgG1-phycoerythrin (open) antibodies. There is no significant difference between the isotype and VEGFR-1 antibody (p  0.5). These
data represent the mean  SEM calculated from three independent monocyte donors.
(C) Nonstimulated CD14 () cells were cultured for 24 hr and were analyzed for VEGFR-1 expression (shaded) and IgG1 (open) compared to
fresh cells (B). There is a significant difference between fresh and nonstimulated monocytes after 24 hr for VEGFR-1 expression (p  0.05).
These data represent the mean  SEM calculated from three independent monocyte donors.
(D) GM-CSF (100 ng/ml)-stimulated CD14 () cells were cultured for 24 hr and were analyzed for VEGFR-1 expression (shaded) and IgG1
(open) compared to fresh cells (B). There is a significant difference in VEGFR-1 expression between fresh and GM-CSF-stimulated monocytes
after 24 hr (p 0.05), and there is no significant difference in VEGFR-1 expression between nonstimulated and GM-CSF-stimulated monocytes
at 24 hr in culture (p  0.2). These data represent the mean  SEM calculated from three independent monocyte donors.
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ng/ml)  rhVEGF (10 ng/ml), rhGM-CSF (100 ng/ml)  (flt-1), it is important to understand if the ratio of soluble
to membrane bound VEGFR is altered by GM-CSF stim-rhVEGF (10 ng/ml)  neutralizing antibodies specific for
sVEGFR-1 (2g/ml), or rhGM-CSF (100 ng/ml) rhVEGF ulation in monocytes. After isolating a fresh population
of CD14 () cells (monocytes) from whole blood (Figure(10 ng/ml)  isotype IgG1 antibodies (2 g/ml) and then
subcutaneously injected the mixture into C57BL/6 fe- 7A), relative expression of membrane bound VEGFR-1
was investigated (Figure 7B). By standardizing the ex-male mice. Qualitative observation of these slides sug-
gested that plugs incubated with both rhGM-CSF (100 pression of VEGFR-1 using an antibody specific for the
receptor and subtracting the relative value of isotypeng/ml) or rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)
(Figures 6E and 6F) had less CD31 () cells compared IgG1, our data show no significant difference in VEGFR-1
expression at the membrane surface at 24 hr betweento plugs treated with rhVEGF (10 ng/ml) (Figure 6B).
Importantly, plugs supplemented with rhGM-CSF (100 nonstimulated and GM-CSF-stimulated cells (p  0.2)
(Figures 7C and 7D).ng/ml)  rhVEGF (10 ng/ml)  neutralizing antibodies
for sVEGFR-1 (Figure 6G) had significantly more CD31
() cells than plugs treated with PBS, rhGM-CSF (100 JAK, JNK, and PI3-Kinase Pathways Are Responsible
ng/ml), rhGM-CSF (100 ng/ml) rhVEGF (10 ng/ml), and for Production of sVEGFR-1 from Monocytes
rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml)  isogenic Since the known biological effects attributed to myeloid
antibodies of the same isotype (mouse IgG1) (Figures progenitor cells by GM-CSF include three known path-
6A, 6E, 6F, and 6H, respectively). When considering ways; JNK (Terada et al., 1997; Nagata et al., 1997), PI3-
CD31 () and CD68 () cell recruitment, CD68 () cell kinase, and JAK (Wojchowski and He, 2001), we assayed
migration was less affected by the addition of GM-CSF the ability of three potent inhibitors of these pathways
than CD31 () cell migration. (SP600125, LY294002, and AG490, respectively) to re-
To quantify differences, digital photographs of the duce the production of sVEGFR-1 from human mono-
H&E-, CD31-, and CD68-stained slides were taken by cytes subsequent to stimulation by GM-CSF. Human
using an inverted, phase-contrast microscope at 400 monocytes were left untreated or were stimulated with
magnification for each sample. Figures 6I illustrates a rhGM-CSF (100 ng/ml) in the presence or absence of
significant reduction in the number of CD31 () cells specific signal transduction inhibitors. Supernatants
invading the plugs treated with PBS, rhGM-CSF (100 were collected and subjected to sVEGFR-1 and VEGF
ng/ml), rhGM-CSF (100 ng/ml)  rhVEGF (10 ng/ml), or ELISAs. Our results indicate a dose-dependent reduc-
rhGM-CSF rhVEGF IgG1 isotype antibodies compared tion in sVEGFR-1 from AG490 (JAK), SP600125 (JNK),
to plugs treated with rhVEGF (10 ng/ml) or rhGM-CSF and LY294002 (PI3-kinase pathway) and restoration of
(100 ng/ml) rhVEGF (10 ng/ml) -VEGFR-1 antibod- VEGF antigenic detection within these same superna-
ies. Of interest, plugs treated with rhGM-CSF had a tants (Figure 7E). Trypan blue analysis was performed to
dose-dependent reduction in relative cell counts (Figure ensure that changes in sVEGFR-1 and VEGF production
6J). In addition, there was no statistical difference be- were not due to toxicity to the cells. Of note, 50 M
tween plugs injected with rhGM-CSF (10 ng/ml) or rhGM- AG490 restored VEGF detection to higher levels than
CSF (100 ng/ml) compared to rhGM-CSF (10 ng/ml)  those seen in nonstimulated cells. We are evaluating the
rhVEGF (10 ng/ml) or rhGM-CSF (100 ng/ml)  rhVEGF possibility that the JAK activity is a negative regulator of
(10 ng/ml), respectively. native VEGF production to explain this finding.
Because there is confusion as to whether recombinant
human GM-CSF can stimulate the maturation of bone Discussion
marrow-derived murine macrophages, we compared
the ability of rhGM-CSF and rmGM-CSF to induce mac- This paper introduces a novel, to our knowledge, role
rophage maturation at 10 days. Using bone marrow ob- for GM-CSF in regulating VEGF activity by stimulating
tained from normal C57BL/6 mice, we found that both secretion of the soluble form of the membrane bound
rhGM-CSF and rmGM-CSF induced more macrophage VEGFR-1 (sVEGFR-1) from human monocytes and thus
maturation than nonstimulated cells (Figure 6K). Of note, inhibiting VEGF-induced angiogenesis, both in vitro
rmGM-CSF at equal concentration was more potent and in vivo.
than rhGM-CSF in promoting maturation (Figure 6L). The impetus of this study emanated from a report
showing that M-CSF (/	) mice were protected from
breast cancer metastases and that overexpressingMembrane Bound VEGFR -1 Expression Is Unchanged
Due to GM-CSF Stimulation M-CSF in the primary tumor induced metastases to a
level seen in wild-type mice (Lin et al., 2001). As a poten-Because sVEGFR-1 is an alternatively spliced variant of
the membrane bound form of the same gene product tial mechanism for this effect, we reported that M-CSF
(E) Monocytes were left untreated (NS), were left untreated with DMSO (NS  DMSO), or were treated with GM-CSF (100 ng/ml) (GM) in
combination with inhibitors (AG490, LY294002, or SP600125) for 24 hr. Supernatants were subjected to sVEGFR-1 (black bars) and VEGF
(white bars) ELISAs. AG490 (JAK2), LY294002 (PI3-kinase), and SP600125 (JNK) reduced the production of sVEGFR-1 (one closed circle, p 
0.05 versus GM-CSF  50 M AG490); two closed circles, p  0.05 versus GM-CSF  20 M LY294002 one closed diamond, p  0.03 versus
GM-CSF  80 M SP600125; and two closed diamonds, p  0.02 versus GM-CSF alone). Concomitantly, all three inhibitors rescued the
detection of VEGF (one open circle, p  0.05 versus GM-CSF  20 M LY294002; two open circles, p  0.02 versus nonstimulated; one open
diamond, p  0.02 versus GM-CSF  80 M SP600125; and two open diamonds, p  0.001 versus GM-CSF  50 M AG490). These data
represent the mean  SEM calculated from three independent monocyte donors.
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induces human monocytes to release biologically active of great interest pharmacologically to understand the
VEGF (Eubank et al., 2003). In the performance of that mechanism by which GM-CSF induces overproduction
study, we observed that GM-CSF-stimulated mono- of sVEGFR-1, a molecule that can sequester VEGF and
cytes had significantly less VEGF compared to both block its activity. sVEGFR-1 mRNA and protein was
rhM-CSF-stimulated and nonstimulated monocytes, as upregulated by GM-CSF, and since there was no change
detected by VEGF ELISA. Now, we report that the reduc- in the amount of VEGFR-1 surface expression on mono-
tion in VEGF observed in response to rhGM-CSF stimu- cytes in GM-CSF-stimulated cells compared to cells left
lation is due to the production of a soluble form of VEGF untreated after 24 hr, we concluded that sVEGFR-1 was
receptor-1. An ELISA specific for human sVEGFR-1 pro- transcriptionally regulated by GM-CSF. However, it is
tein showed that monocytes produced significantly possible that GM-CSF induced the production of an
more sVEGFR-1 in response to GM-CSF than in re- intermediate factor to account for sVEGFR-1 expres-
sponse to M-CSF or those left untreated. These data sion. To dissect the signaling pathways involved, we
were further supported by real-time PCR analysis show- used pharmacological inhibitors instead of transfection
ing that sVEGFR-1 mRNA in GM-CSF-stimulated mono- studies because of the difficulty in transfecting primary
cytes peaked at 48 hr, while there was no increase in human monocytes, and we found that JAK, JNK, and
mRNA levels in nonstimulated cells. Likewise, GM-CSF- PI3-kinase inhibitors reduced the production of sVEGFR-1
stimulated monocytes produced a dose-dependent in- in GM-CSF-stimulated monocytes and recovered detec-
crease in sVEGFR-1 mRNA transcription and subse- tion of VEGF in the samples.
quent protein expression, which was significantly greater The observation that rhGM-CSF stimulates human
than in nonstimulated samples. monocytes to release sVEGFR-1 and inhibit VEGF-
To investigate the mechanism of loss in antigenic induced angiogenesis has direct impact on solid organ
VEGF detection in the supernatants of GM-CSF-stimu- tumors, in which monocyte and macrophage influx into
lated monocytes, these supernatants were incubated primary tumors under the influence of M-CSF stimula-
with neutralizing antibodies specific for sVEGFR-1 to tion may enhance tumor metastases (Lin et al., 2001),
rescue rhVEGF detection. As predicted, rhVEGF detec- perhaps through the production of VEGF (Eubank et
tion was restored in samples incubated with antibodies al., 2003). The observation that rhGM-CSF reduces the
to sVEGFR-1, while incubation with isogenic IgG anti- biological activity of VEGF suggests that in addition to
bodies did not restore VEGF detection. Of note, while promoting granulocyte production after chemotherapy,
neutralizing antibodies to sVEGFR-1 restored detection rhGM-CSF may also have antitumor effects through the
of exogenous rhVEGF, neutralizing antibodies did not ability to reduce tumor metastases and angiogenesis.
rescue detection of endogenous VEGF released in the Pharmacologically, GM-CSF is currently used in therapy
supernatants of GM-CSF-stimulated monocytes. We to treat a number of conditions related to neutropenia
speculate that the affinity of preformed protein-receptor and bone marrow transplantation. Existing treatment
complexes was too strong for the antibodies to disrupt, strategies for recovery of bone marrow in transplant
while antibodies added to these supernatants prior to patients include 125–250g/m2 given daily by IV infusion
adding rhVEGF allowed competitive inhibition of binding over 2 hr, beginning within 2 hr after allogeneic BMT
of rhVEGF to the sVEGFR-1. (bone marrow transplantation) and continuing for up to
Next, we wanted to know if supernatants from GM- 27 days. However, as opposed to systemic administra-
CSF-stimulated monocytes containing sVEGFR-1 inhib- tion of rhGM-CSF to induce bone marrow recovery, our
ited tube formation of endothelial cells in an in vitro data suggest that local injection of rhGM-CSF may be
Matrigel angiogenesis model. Cell-free supernatants needed to reduce tumor metastases through the pro-
from GM-CSF-stimulated monocytes inhibited HUVEC duction and release of sVEGFR-1 by monocytes.
tube formation compared to supernatants from nonstim- Soluble VEGFR-1 treatment in tumors is a valid ap-
ulated cells, confirming that GM-CSF induced mono-
proach, as past studies with various forms of sVEGFR-1
cytes to produce antiangiogenic molecules. More im-
have targeted VEGF and reduced its angiogenic effects
portantly, in vivo data showed that mice injected with
(Goldman et al., 1998). Currently, a “decoy” soluble re-Matrigel plugs supplemented with recombinant rhGM-
ceptor, known as VEGF-TRAP, composed of the firstCSF  rhVEGF had significantly less angiogenesis into
three Ig-like domains of VEGFR-1 fused to the constantthese plugs compared to plugs supplemented with
region (Fc) of human IgG1 effectively suppresses tumorrhVEGF. Similarly, CD31 () cells that invaded the plugs
growth and vascularization in vivo (Holash et al., 2002).were proportional to bioavailable antigenic VEGF. In
To our knowledge, this is the first report to show thatcontrast, infiltration of CD68 () cells within these plugs
monocytes are an endogenous source of sVEGFR-1was not statistically different in any condition. These
from GM-CSF treatment. At present, we are investigat-data suggest that CD68 () cells were responding to
ing the involvement of M-CSF and GM-CSF and theirGM-CSF to regulate VEGF activity and inhibit recruit-
effects on monocytes and macrophages in both physio-ment of endothelial cells. The mechanism for the differ-
logical and pathophysiological angiogenesis utilizingences in angiogenesis seen in plugs treated with or
murine models.without rhGM-CSF likely reflects the relative production
of sVEGFR-1 in GM-CSF-stimulated samples, as anti-
Experimental Proceduresbodies to sVEGFR-1 in rhGM-CSF-treated Matrigel plugs
restored blood vessel formation and CD31 () cell recruit- Materials
ment to levels seen in plugs incubated with rhVEGF alone. Blood donors were obtained from the American Red Cross. Fetal
Since it has been shown that certain tumors can me- bovine serum (FBS) (certified  0.06 EU/ml endotoxin levels) was
obtained from Hyclone Laboratories. Recombinant human (rh)GM-tastasize in the presence of VEGF (Folkman, 1990), it is
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CSF, rhVEGF, rh-sVEGFR-1, the human VEGF Duoset ELISA Devel- U01134). 2 Universal Master Mix was used in the reaction mixture
containing 0.83 l of 12 M each forward and reverse primers, 200opment Kit, and the human sVEGFR-1 Quantitikine Kit were pur-
chased from R&D Systems. -human VEGFR-1 antibody was nM probe (FAM-MGB), 0.25 l “20” 18S internal control probe
(VIC-MGB), 17.3 l DEPC-treated water, and 4 l cDNA from eachpurchased from Sigma-Aldrich. Growth Factor-Reduced Matrigel ma-
trix and BD Biocoat Invasion Chambers were purchased from Dis- sample for a 50 l total reaction volume. The real-time polymerase
chain reaction was completed on the ABI Prism Sequence Detectorcovery Labware. Human Umbilical Vein Endothelial Cells (HUVECs),
Endothelial Basal Medium (EBM), and EGM Singlequots were all 7700 (Perkin-Elmer) by using Sequence Detector v1.7 software. Re-
action conditions were as follows: 50C for 2 min, 95C for 10 min,purchased from BioWhittaker, Inc. The absolutely RNA RT-PCR Mini-
prep Kit for total RNA purification was purchased from Stratagene. 40 cycles of 95C for 15 s, and 60C for 1 min. Fold induction or
reduction of VEGF or soluble VEGFR-1 mRNA was calculated asThe SuperScript First-Strand Synthesis System for RT-PCR Kit for
cDNA synthesis was purchased from GIBCO-BRL. Taqman Univer- previously described (Eubank et al., 2003).
sal PCR Master Mix was obtained from Applied Biosystems. The
human sVEGFR-1 (sFlt-1) probe (5
-6FAM-CTGTTTTCTCTCGGA
In Vitro HUVEC Tube Formation AssayTCT-MGB- 3
), the sFlt-1 Forward Primer (5
-AGGTGAGCACTG
Isolated monocytes were left nonstimulated or were stimulated withCAACAAAAAG-3
), and the sFlt-1 Reverse Primer (5
-GTGGTA
rhGM-CSF (100 ng/ml) and incubated at 37C, in 5% CO2, for 24 hr.CAATCATTCCTTGTGCTT-3
) were designed by using Primer Ex-
Cell-free supernatants were harvested and then frozen at 	80C.press v1.0 software (ABI Prism, Perkin-Elmer) and synthesized by
Prior to using these rhGM-CSF-stimulated monocyte supernatants,Applied Biosystems. The primers and probe sequence specific for
all remaining rhGM-CSF was immunodepleted by using -rhGM-VEGF mRNA analysis by real-time PCR are as previously described
CSF antibodies (2 g/ml) at 4C for 2 hr and was subjected to(Eubank et al., 2003). C57BL/6 female mice were purchased from
protein G agarose beads for removal. HUVECs were cultured inJackson Laboratories. Human serum albumin (0.1%) was added to
these supernatants by using growth factor-depleted Matrigel. Anti-all samples to act as a carrier for recombinant VEGF. The JAK
angiogenic activity was assessed by the inhibition of branch pointsinhibitor (JAK2 and JAK3) AG490, the PI3-kinase inhibitor LY294002,
from capillary-like tube structures formed between the endothelialand the JNK inhibitor SP600125 were purchased from Calbiochem.
cells. Matrigel was distributed in a 96-well plate (60 l/well) and
allowed to solidify at 37C. HUVECs (passes 1–4) were serum starvedMonocyte Isolation
in EBM for 2 hr. All controls and samples were resuspended in EBMSingle donor monocytes were isolated either from source leukocyte
and had 1.5  105 HUVECs/well. All components were rotated atpacks obtained from the American Red Cross or by negative selec-
4C for at least 1 hr before addition to HUVECs. The culture wastion from fresh blood by using the Monocyte Negative Isolation
incubated at 37C for 20 hr. Tube formation was observed, andKit (Miltenyi Biotec). Of note, monocyte purity is 90% as per the
digital pictures were captured. Quantification of antiangiogenic ac-manufacturer. For all experiments, monocytes were resuspended
tivity was measured by counting branch points from tubes formedin either 5  106 or 10  106 cells/condition in RPMI-1640  0.1%
between discrete endothelial cells in each well relative to the positivehuman serum albumin (HSA)  10 g/ml polymyxin B and were left
control (2.5 ng/ml rhVEGF). Total branch points in three high-pow-nonstimulated or stimulated with 100 ng/ml rhM-CSF or rhGM-CSF.
ered fields were counted per well in a blinded manner. Additionally,Polymyxin B was added as further protection against endotoxin
HUVECs were cultured in EBM alone, with rhVEGF (5 ng/ml), or withcontamination in cell cultures.
rhVEGF (5 ng/ml)  recombinant sVEGFR-1 (50 ng/ml) and were
allowed to incubate at 37C for 16 hr. Five photographs per wellVEGF and sVEGFR-1 Production Measured by ELISA
were taken, and the number of tube branch points were quantifiedHuman monocytes were stimulated immediately after isolation by
as indicated above.100 ng/ml rhM-CSF or rhGM-CSF, or they were left untreated and
then incubated at 37C, 5% CO2 for the indicated time (0, 24, or
48 hr); cell-free supernatants were collected. For inhibitor studies,
In Vivo Matrigel Plug Assaycompounds were added to monocytes for 30 min at 37C, and the
Six-week-old C57BL/6 female mice were anesthetized with isoflur-cells were stimulated or left untreated for 24 hr.
ane and subcutaneously injected with 0.5 ml growth factor-reduced
Matrigel matrix supplemented with either PBS  0.1% HSA, 1, 10,
VEGF and sVEGFR-1 Measurement in Monocytic or 100 ng/ml rhM-CSF; 10 ng/ml rhVEGF alone or in combination
Whole-Cell Lysates with 1, 10, or 100 ng/ml rhGM-CSF; or 100 ng/ml rhGM-CSF incu-
Isolated monocytes were stimulated with 1, 10, or 100 ng/ml rhGM- bated with 2 g/ml sVEGFR-1 neutralizing antibodies or isotype
CSF and were analyzed as previously described (Eubank et al., antibodies. All components added to the unpolymerized Matrigel
2003). were allowed to incubate at 4C for at least 4 hr prior to injection.
After 10 days, the mice were sacrificed and skinned, and the Matrigel
35S-Methionine/Cysteine Labeling of VEGF plugs were removed and flash-frozen in liquid nitrogen. At least
Freshly isolated monocytes were either left nonstimulated or were three mice were used per experimental group.
stimulated with rhM-CSF (100 ng/ml) or rhGM-CSF (100 ng/ml) and
5% CO2 for 36 hr at 37C. All supernatants were aspirated, and fresh
DMEM (methionine/cysteine-free) media (1 ml) was added to each Histology
sample, followed by 50 Ci/ml of both 35S-methionine and 35S-cys- Total cellular influx within the plugs was determined by using H&E
teine for 12 hr. The cultured monocytes were centrifuged at 5,000 stain. Photographs of randomly selected high-powered fields with
rpm for 5 min, and the supernatants were collected and incubated a 40 objective lens were captured for each sample, and they were
with heparin agarose for 2 hr at 4C to isolate labeled VEGF and then counted in a blinded manner and averaged. Relative cell counts
were separated on an 8% SDS-PAGE gel. Gels were dried and per high-powered field were quantified by counting individual endo-
subjected to densitometry by using a phosphorimager. VEGF was thelial cells, identified by CD31 immunostaining (50:1 in PBS for 1 hr
identified by the predicted molecular weight and by comparison to at room temperature, followed by three washes in PBS for a total
the band purified from M-CSF-stimulated monocytes, used as a of 30 min for frozen sections) or by von Willebrand factor immuno-
positive control for VEGF production. staining (by Dr. Donna Kusewitt, Veterinary Pathology, Director of
Veterinary Biosciences and Histology/Immunohistochemistry, The
Total RNA Isolation from Monocytes Ohio State University, for formalin-fixed, paraffin-embedded sec-
Monocyte total RNA was collected as previously described (Eubank tions), which passed inside the perimeter of the Matrigel plug and
et al., 2003). contributed to the composition of a blood vessel. Mononuclear cells
were identified by CD68 immunostaining (200:1 in PBS for 1 hr at
room temperature, followed by three washes in PBS for a total ofReal-Time Polymerase Chain Reaction
Soluble VEGFR-1 primers and probe with MGB quencher were de- 30 min). “Angiogenesis” is defined as the process of vascularization
involving development of blood vessels within the Matrigel plugs.signed based on the human sVEGFR-1 sequence (accession
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FLOW Analysis for VEGFR-1 Expression Yancopoulos, G.D., and Rudge, J.S. (2002). VEGF-Trap: a VEGF
blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USAHuman monocytes isolated from whole blood were cultured for 24
hr in EBM and were either left untreated or were treated with 100 99, 11393–11398.
ng/ml rhGM-CSF and were subsequently counted and stained for Kendall, R.L., Wang, G., and Thomas, K.A. (1996). Identification of
the expression of membrane bound VEGFR-1 by using either mouse a natural soluble form of the vascular endothelial growth factor
-human VEGFR-1-phycoerythrin mAb (R&D Systems) or mouse receptor, FLT-1, and its heterodimerization with KDR. Biochem. Bio-
IgG1-phycoerythrin isotype antibody (Pharmingen). phys. Res. Commun. 226, 324–328.
Kliche, S., and Waltenberger, J. (2001). VEGF receptor signaling and
Statistical Analyses endothelial function. IUBMB Life 52, 61–66.
Minitab statistical software utilizing a nonparametric ANOVA with
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., and Fer-Tukey’s post-hoc test was performed to determine differences be-
rara, N. (1989). Vascular endothelial growth factor is a secretedtween groups by using MiniTab software. Groups were considered
angiogenic mitogen. Science 246, 1306–1309.significantly different at p  0.05.
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